---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034585"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T05:52:05.161753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%

## Summary
- Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.
- Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.
- CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.
- CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.
- January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment.

## SEC filing metadata
- accession: 0000950170-25-034585
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/0000950170-25-034585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/ctmx-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034585
- JSON: https://secwatch.observer/filing/0000950170-25-034585.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.